Evidence Hub

Pharmacologic management of postoperative sleep disturbance in breast cancer

Bu F, Zeng S, Liu Q, Lou Z, Ma C, Peng Y, Xiong L, Wen Y et al.

Frontiers in pharmacology, 2026

Abstract

Postoperative sleep disturbance (PSD) is a common yet underrecognized complication after breast cancer surgery and is associated with pain, fatigue, affective symptoms, impaired quality of life, and delayed postoperative recovery. Its management remains challenging because symptom presentations are clinically heterogeneous, and treatment decisions must balance therapeutic efficacy with safety within the broader context of breast cancer care and survivorship. This narrative review summarizes the current evidence on PSD after breast cancer surgery, with particular emphasis on pharmacologic management, therapeutic positioning, and breast cancer-specific safety considerations. Available evidence suggests that a phenotype-guided pharmacologic management framework may be clinically useful, although this approach remains conceptual and has not yet been prospectively validated in postoperative breast cancer populations. Short-course hypnotics may be considered for acute insomnia characterized by prominent nocturnal hyperarousal, whereas melatonin and melatonin receptor agonists may be particularly relevant when circadian disruption predominates. In contrast, gabapentinoids and multimodal analgesic strategies may be more appropriate for pain-dominant or mixed symptom presentations. Across drug classes, treatment selection should account for cumulative sedative burden, respiratory risk associated with concurrent opioid use, next-day cognitive adverse effects, and endocrine therapy…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free